Ertugliflozin L-pyroglutamic acid structure
|
Common Name | Ertugliflozin L-pyroglutamic acid | ||
---|---|---|---|---|
CAS Number | 1210344-83-4 | Molecular Weight | 565.997 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C27H32ClNO10 | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of Ertugliflozin L-pyroglutamic acidErtugliflozin (PF-04971729) L-pyroglutamic acid is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2[1]. A drug for the treatment of type 2 diabetes mellitus[2]. |
Name | Ertugliflozin L-pyroglutamic acid |
---|---|
Synonym | More Synonyms |
Description | Ertugliflozin (PF-04971729) L-pyroglutamic acid is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2[1]. A drug for the treatment of type 2 diabetes mellitus[2]. |
---|---|
Related Catalog | |
Target |
IC50: 0.877 nM (h-SGLT2)[1]. |
In Vitro | Ertugliflozin (PF-04971729) demonstrates >2000-fold selectivity for SGLT2 inhibition (relative to SGLT1) in vitro[3]. |
In Vivo | Ertugliflozin (PF-04971729) reveals a concentration-dependent glucosuria after oral administration to rats[3]. |
References |
Molecular Formula | C27H32ClNO10 |
---|---|
Molecular Weight | 565.997 |
Exact Mass | 565.171448 |
Storage condition | 2-8℃ |
MLU731K321 |